Virios Therapeutics (VIRI) Insider Trading & Ownership $4.76 -0.23 (-4.61%) As of 07/11/2025 Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock Virios Therapeutics (NASDAQ:VIRI) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage12.20%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$51.19KNumber OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$468.00 Get VIRI Insider Trade Alerts Want to know when executives and insiders are buying or selling Virios Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address VIRI Insider Buying and Selling by Quarter Virios Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/21/2023William PridgenDirectorBuy15,335$1.30$19,935.50 8/17/2023Gregory Scott DuncanCEOBuy25,000$1.25$31,250.00 12/8/2022Richard James WhitleyDirectorSell1,800$0.26$468.00 (Data available from 1/1/2013 forward) VIRI Insider Trading Activity - Frequently Asked Questions Who is on Virios Therapeutics' Insider Roster? The list of insiders at Virios Therapeutics includes Gregory Scott Duncan, Richard James Whitley, and William Pridgen. Learn more on insiders at VIRI. What percentage of Virios Therapeutics stock is owned by insiders? 12.20% of Virios Therapeutics stock is owned by insiders. Learn more on VIRI's insider holdings. Which Virios Therapeutics insiders have been buying company stock? The following insiders have purchased VIRI shares in the last 24 months: Gregory Scott Duncan ($31,250.00), and William Pridgen ($19,935.50). How much insider buying is happening at Virios Therapeutics? Insiders have purchased a total of 40,335 VIRI shares in the last 24 months for a total of $51,185.50 bought. Virios Therapeutics Key ExecutivesMr. Gregory Duncan (Age 59)Chairman & CEO Compensation: $566.92kDr. William L. Pridgen M.D. (Age 63)Founder & Director Compensation: $35kMs. Angela Walsh (Age 57)CFO, SVP of Finance, Corporate Secretary & Treasurer Compensation: $282.64kDr. R. Michael Gendreau M.D. (Age 68)Ph.D., Chief Medical Officer Compensation: $364.94kMr. Ralph D. Grosswald M.P.H. (Age 55)Senior Vice President of Operations Compensation: $274.69kMs. Carol Duffy Ph.D.Chief Scientific Advisor More Insider Trading Tools from MarketBeat Related Companies Arcturus Therapeutics Insider Selling MBX Biosciences Insider Selling Compass Therapeutics Insider Selling Terns Pharmaceuticals Insider Selling Humacyte Insider Selling Prothena Insider Selling Heron Therapeutics Insider Selling Amarin Insider Selling Prime Medicine Insider Selling Aquestive Therapeutics Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Do They Know Something? Insiders & Congress Buy UnitedHealthMicron Insiders Sell But Investors Should Buy, Buy, BuySizzling Insider Buys for Your High-Yield WatchlistInsider Selling at NVIDIA Could Turn Into an Opportunity The Top Insider Sells From Q2: Buy, Sell, or Hold? This page (NASDAQ:VIRI) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.